Connect with organ transplant patients, caregivers, and medical professionals to share experiences about acute rejection, immunosuppression, and post-transplant care.
Posted by KidneyRecipient2023 · 54 replies
Early signs of acute kidney rejection include a sudden decrease in urine output, pain or tenderness at the transplant site (usually lower abdomen), unexplained fever above 38°C (100.4°F), and a rapid rise in serum creatinine levels. Many rejection episodes are asymptomatic and only caught through routine lab monitoring, which is why regular post-transplant blood tests are critical. If you notice any of these signs, contact your transplant center immediately — early intervention with pulse steroids or other anti-rejection treatments is much more effective than delayed treatment.
Posted by TransplantNurse · 38 replies
Acute cellular rejection (ACR) is mediated by T-lymphocytes that directly attack the transplanted organ, and it typically responds well to high-dose corticosteroid treatment. Antibody-mediated rejection (AMR) involves donor-specific antibodies (DSAs) that target the graft vasculature and is generally harder to treat, often requiring plasmapheresis, intravenous immunoglobulin (IVIG), and rituximab. A kidney biopsy using the Banff classification system is the gold standard for distinguishing between these types. Mixed rejection involving both T-cell and antibody components is increasingly recognized and requires combination therapy.
Posted by LiverPatient · 29 replies
Tacrolimus (FK506) has a half-life of approximately 12 hours in most adult transplant patients, so it takes roughly 3-4 days (about 5 half-lives) to reach a new steady-state after a dose change. Your transplant coordinator will typically check your trough level (blood drawn just before the next dose) 3-5 days after any adjustment. Factors that affect tacrolimus absorption include grapefruit juice, St. John's Wort, certain antibiotics (erythromycin, fluconazole), and genetic variations in CYP3A5 metabolism. Never adjust your tacrolimus dose without guidance from your transplant team.
Posted by HeartRecipient · 47 replies
Live vaccines (MMR, varicella, yellow fever, live influenza) are generally contraindicated in immunosuppressed transplant recipients due to risk of vaccine-strain infection. Inactivated vaccines are safe and strongly recommended: annual influenza (inactivated), pneumococcal (Prevnar 20 or PPSV23), hepatitis B, and now COVID-19 vaccines. However, vaccine responses may be blunted by immunosuppression — studies show that transplant recipients often have lower seroconversion rates than healthy individuals. Discuss your complete vaccination status with your transplant team before any travel or new vaccine.
Posted by NewKidneyPatient · 22 replies
Mycophenolate mofetil (MMF) is best absorbed on an empty stomach, but if GI side effects are problematic, taking it with a small amount of food can help. Avoid antacids containing magnesium or aluminum hydroxide, as they can reduce MMF absorption by up to 33%. High-fiber foods and cholestyramine also bind MMF and reduce its effectiveness. Unlike tacrolimus, grapefruit is not a concern for MMF. Proton pump inhibitors (PPIs) like omeprazole can reduce the area under the curve (AUC) of MMF — inform your transplant team if you use them regularly.
Posted by TenYearSurvivor · 63 replies
Chronic rejection (now often called chronic allograft dysfunction) develops over months to years and is characterized by progressive fibrosis, vascular changes, and gradual loss of organ function. Unlike acute rejection, it rarely responds to increased immunosuppression and currently has no proven reversal treatment. In the kidney, it manifests as chronic allograft nephropathy with rising creatinine, proteinuria, and hypertension. Minimizing modifiable risk factors — controlling blood pressure, avoiding nephrotoxic drugs, maintaining therapeutic immunosuppression levels, and treating acute rejections promptly — is the best strategy to slow progression.
Posted by TransplantCoord · 41 replies
Most kidney transplant centers use triple immunosuppression: a calcineurin inhibitor (tacrolimus, preferred over cyclosporine at most centers), an antimetabolite (mycophenolate mofetil or mycophenolate sodium), and a corticosteroid (usually prednisone tapered from high to low doses over 3-6 months post-transplant). Induction therapy with a biological agent (basiliximab or anti-thymocyte globulin, depending on immunologic risk) is administered perioperatively. Some programs pursue steroid withdrawal or minimization at 3-6 months in low-risk patients to reduce long-term metabolic side effects.
Posted by PathologyStudent · 18 replies
The Banff classification is the internationally standardized system for grading kidney transplant rejection in biopsy specimens. It scores features like tubulitis (t score, 0-3), interstitial infiltration (i score, 0-3), intimal arteritis (v score, 0-3), glomerulitis (g score), and peritubular capillaritis (ptc score). Banff 1A/1B indicates mild-moderate acute cellular rejection, while 2A/2B indicates vascular rejection. Banff category III (v3) is severe rejection affecting major vessel walls. The 2022 Banff update incorporated molecular markers and integrates molecular rejection phenotyping for more precise diagnosis.
Posted by LivingWellPost · 35 replies
The primary driver of acute rejection is immunological — it is not directly caused by psychological stress. However, stress can indirectly increase rejection risk if it leads to missed doses of immunosuppressive medication, which is one of the most common precipitants of late acute rejection. Non-adherence to tacrolimus has been associated with a 7-fold higher risk of late acute rejection in kidney transplant recipients. Establishing a pill routine, using medication reminder apps, and communicating openly with your transplant team about barriers to adherence are the most important lifestyle interventions.
Posted by MedStudent2025 · 27 replies
Human Leukocyte Antigen (HLA) matching between donor and recipient reduces the risk of both acute and chronic rejection. Better HLA compatibility means the recipient's immune system is less likely to recognize the donor organ as foreign. For kidney transplants, 6-antigen HLA matches (zero mismatches) have the best long-term outcomes and are shared nationally through UNOS. However, even well-matched kidneys can be rejected if the recipient has pre-existing donor-specific antibodies (DSAs). Pre-transplant crossmatch testing and panel reactive antibody (PRA) screening identify these antibodies to prevent hyperacute rejection.